Prologis Inc vs Revvity Inc — how do they compare? Prologis Inc trades at $129.1 (market cap $122.87B), while Revvity Inc trades at $154.72 (market cap $16.98B). The key difference: Prologis Inc is far larger — about 7.2× Revvity Inc's market cap, and Prologis Inc pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Prologis Inc for 102 Days and Revvity Inc for 12 Days on average.
| PLD | RVTY | |
|---|---|---|
Market Cap | $122.87B | $16.98B |
Volume | 4,222,957 | 1,456,900 |
Sector | Real Estate | Health |
52-Week High | $149.96 | $157.36 |
52-Week Low | $111.23 | $82.26 |
Typical Hold Time | 102 Days | 12 Days |
Enterprise Value | $157.61B | $19.30B |
Dividend Yield | 3.31% | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Prologis (PLD) trades at $127.3, down 1.07% on the day, amid a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is steady, supported by robust leasing activity and data center expansion, while profitability remains high with a net income margin of 45.79%. Analyst consensus is bullish with a $155.15 price target, though technical indicators show near-term pressure.
The outlook for PLD is positive due to its leading position in industrial real estate, driven by e-commerce and data center demand. Risks include rising debt levels and market volatility. Institutional buying and strong analyst support suggest long-term upside, but investors should monitor debt management and macroeconomic trends affecting REIT valuations.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →